F-18 FDG PET-positive Fibrous Dysplasia in a Patient with Intestinal Non-Hodgkin's Lymphoma
Open Access
- 1 January 2009
- journal article
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 41 (3), 171-174
- https://doi.org/10.4143/crt.2009.41.3.171
Abstract
Fibrous dysplasia (FD) is a common benign bone disorder of an unclear etiology. It is known that FD can appear without an increased FDG uptake on F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). However, there are also several reports that FD showed increased FDG uptake and this mimicked malignant bone involvement on FDG-PET. Herein we describe a case of biopsy-proven FDG-PET positive FD in a patient with intestinal non-Hodgkin's lymphoma (NHL). A 45-year-old woman was diagnosed with intestinal NHL, which was removed by right hemicolectomy. After the operation, the FDG-PET/CT scan showed hypermetabolic activity in the right transverse process of the T10 vertebra. The patient then received a total of 6 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy every 3 weeks. After completion of the planned chemotherapy, the 2(nd) FDG-PET/CT showed increased FDG uptake (SUVmax=6.0 g/mL) of the previous bone lesion. The MR images revealed a T1-hypointense lesion with sharp borders in the same region, and this showed homogenous contrast enhancement on the fat-suppressed T1-weighted images. After the radiologic studies were carefully reviewed, the bone lesion was assumed to be benign such as FD. We performed bone biopsy and the histological examination confirmed the diagnosis of FD. In conclusion, bone lesions with FDG uptake need to be carefully interpreted when evaluating patients with known malignancy.Keywords
This publication has 15 references indexed in Scilit:
- 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrenceAnnals of Nuclear Medicine, 2008
- F-18 Fluorodeoxyglucose (FDG) PET in the Diagnosis of Malignant Transformation of Fibrous Dysplasia in the Pelvic BonesClinical Nuclear Medicine, 2008
- Intensity of FDG Uptake Is Not EverythingClinical Nuclear Medicine, 2008
- Avid uptake of [18F]-FDG in fibrous dysplasia can mimic skeletal involvement in Hodgkin’s diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- PET-positive fibrous dysplasia - a potentially misleading incidental finding in a patient with intimal sarcoma of the pulmonary arterySkeletal Radiology, 2007
- Unexpected finding of elevated glucose uptake in fibrous dysplasia mimicking malignancy: contradicting metabolism and morphology in combined PET/CTEuropean Radiology, 2006
- Bone Metastasis Detected by FDG PET in a Patient With Breast Cancer and Fibrous DysplasiaClinical Nuclear Medicine, 2005
- FDG PET of Primary Benign and Malignant Bone Tumors: Standardized Uptake Value in 52 LesionsRadiology, 2001
- Increased bone mineral turnover without increased glucose utilization in sclerotic and hyperplastic change in fibrous dysplasia.Annals of Nuclear Medicine, 1998
- Tumor metabolic rates in sarcoma using FDG PET.1998